Literature DB >> 17085314

Rituximab responsive refractory acute graft-versus-host disease.

R Kamble, M Oholendt, G Carrum.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17085314     DOI： 10.1016/j.bbmt.2006.06.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  3 in total

1.  Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Thomas F Michniacki; Sung Won Choi; Daniel C Peltier
Journal:  Handb Exp Pharmacol       Date:  2022

2.  Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Ginna G Laport; Juan Wu; Brent Logan; Veronika Bachanova; Chitra Hosing; Timothy Fenske; Walter Longo; Steven M Devine; Auayporn Nademanee; Iris Gersten; Mary Horowitz; Hillard M Lazarus; Marcie L Riches
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-23       Impact factor: 5.742

3.  Rippled skin, fasciitis, and joint contractures.

Authors:  Asha R Patel; Daniele Avila; Harry L Malech; Steven Z Pavletic; Larry Yao; Edward W Cowen
Journal:  J Am Acad Dermatol       Date:  2008-12       Impact factor: 11.527
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.